News > Elacestrant improves outcomes for ER+ metastatic breast cancer

Elacestrant improves outcomes for ER+ metastatic breast cancer

Preliminary findings offer positive news for people with hormone receptor-positive cancer

disclaimer_box

Editor’s note: On January 30, 2023, elacestrant (Orserdu) was FDA-approved to treat hormone receptor-positive, HER2-negative advanced or metastatic breast cancer that has tested positive for an ESR1 mutation with disease progression following treatment with at least one hormonal therapy. Read more about elacestrant.

featured_paragraph

Elacestrant, an endocrine therapy taken in pill form, emerges as a new option for people with ER+/HER2- metastatic breast cancer.

general_content

An update on the EMERALD clinical trial was presented on December 8, 2021 at the San Antonio Breast Cancer Symposium. The preliminary results show that people with hormone-positive cancer may benefit more from elacestrant than current standard therapies.

Background


Endocrine (or hormone) therapy plus CDK 4/6 inhibitors is the standard first treatment for ER+/HER2- metastatic disease. The endocrine therapy often takes the form of fulvestrant. In most people, the medicines ultimately fail to stop cancer from progressing. The cancer becomes resistant to treatment, sometimes due to a change in the ESR1 gene. This gene is increasingly being looked at as a marker for how people respond to treatment.



Fulvestrant was approved nearly 20 years ago. While no other drug has shown better results, fulvestrant used on its own does a poor job in keeping cancer from growing or spreading. For this reason, finding better endocrine therapies for metastatic breast cancer is a high priority.

Results



The phase III study randomized 477 men and postmenopausal women to two groups of similar size. The average age of participants was 63. All were ER+ and negative for HER2. Their cancers had progressed or relapsed on or after one or two lines of endocrine therapy, one with a CDK 4/6 inhibitor. Some participants had received one line of chemotherapy as well.



The study group received elacestrant. Doctors chose between fulvestrant or one of three aromatase inhibitors as the endocrine therapy for the control group. Most chose fulvestrant. The study looked at disease progression and overall survival.



The results were positive. Elacestrant resulted in a 30 percent reduction in disease progression or death compared to the control group. People whose cancers test positive for ESR1 saw an even greater reduction (45 percent). Progression-free survival was higher at both 6 and 12 months, as compared to the overall control group and to the subgroup of the control group taking fulvestrant.



The benefit was seen in participants older and younger than 65, in multiple races, across study sites in 17 countries. It was even seen in people who had been treated previously with fulvestrant, suggesting a more powerful endocrine therapy may still be effective with this group even after fulvestrant stops working.



Nausea was the main side effect, reported at higher rates than typical with endocrine therapy. Around 35 percent of participants taking the drug experienced nausea. Details on the severity of the nausea was not available. Other common side effects included fatigue and hot flashes, similar to other endocrine therapies.



There were no safety concerns with elacestrant. Participants who dropped out of the trial did so because of disease progression, not side effects.

What it means for people with ER+ metastatic breast cancer



Elacestrant is the first oral SERD to show improvement over the standard treatment. This is exciting news for people with ER+/HER2- metastatic breast cancer whose cancers do not respond to fulvestrant or aromatase inhibitors. Cancers that test positive for ESR1+ may be even more likely to benefit from the drug.



These results are preliminary, and it’s worth noting that this drug is not yet approved by the U.S. Food and Drug Administration. The final analyses will come out in late 2022 or early 2023. This study only included postmenopausal women and men because there was no safety information on premenopausal women. Future studies may include younger women.



Initial results suggest that the drug may cause nausea at a higher rate than other endocrine therapies. More information on the severity of nausea may be available in the future. In addition, the cost of elacestrant is not yet known. It will likely be higher than fulvestrant, which is available in generic form.

related_resources_article_carousel

Related resources

Tests for metastatic breast cancer

04/17/24 | BY: Debu Tripathy

Many different tests can be involved in a metastatic breast cancer diagnosis. These tests can confirm the extent of the cancer and determine the most effective treatments.

Read More
 | 11 Min. Read |

PET Scan

02/28/24 | BY: Sophia R. O'Brien

A PET scan is an imaging test used to detect cancer throughout the body. They are not used to screen for breast cancer, but can help you and your healthcare team make decisions about treatment.

Read More
 | 8 Min. Read |

Treatment for metastatic breast cancer

02/12/24 | BY: Douglas Yee

The goal of metastatic breast cancer treatment is to manage the disease while limiting side effects. Learn about available treatments and when they are used.

Read More
 | 22 Min. Read |

Capivasertib

02/03/24 | BY: Sameer Gupta

Capivasertib (Truqap) is a targeted therapy used to treat hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancers that test positive for certain gene mutations

Read More
 | 9 Min. Read |

ESR1 mutation testing

11/27/23 | BY: Virginia Kaklamani

Over time, metastatic breast cancers treated with endocrine therapy can develop a mutation in a gene called ESR1, which may develop treatment resistance.

Read More
 | 7 Min. Read

Tamoxifen

08/05/23 | BY: Reshma L. Mahtani

Tamoxifen is a type of hormonal therapy called a SERM, or selective estrogen receptor modulator, a medicine that prevents estrogen signals from getting to breast cancer cells.

Read More
 | 11 Min. Read |

Hormone receptor-positive MBC

07/26/23 | BY: Pallav K. Mehta

Learn more about hormone receptor-positive metastatic breast cancer, which means the stage IV breast cancer is hormone-sensitive.

Read More
 | 6 Min. Read |

Types of hormonal therapy

05/23/23 | BY: Jennifer Winn

Hormonal therapy medicines are in classes based on how they interact with the body’s natural hormones estrogen & progesterone. Some stop the body from making estrogen; others prevent estrogen from helping the cancer cell grow

Read More
 | 6 Min. Read |

Triple-negative metastatic breast cancer

05/01/23 | BY: Rita Nanda

Metastatic triple-negative breast cancer is a rare form of aggressive breast cancer. Learn more its symptoms, diagnosis, and treatment options.

Read More
 | 11 Min. Read |

Ribociclib

04/21/23 | BY: Sameer Gupta

Ribociclib (Kisqali), a targeted therapy, is the second CDK 4/6 inhibitor to be approved by the FDA. It targets two specific kinases, or enzymes, that help tumor cells grow and divide.

Read More
 | 6 Min. Read |
about_this_page_tabbed_module
About this page
Glossary
About LBBC

Jamie Kudera

Placeholder silhouette
  • Has been a contributor to LBBC since 2021
  • Reports on major scientific meetings and works to ensure LBBC's web content is current

Reviewed and updated: May 23, 2023

Tagged:

Was this page helpful?

Living Beyond Breast Cancer is a national nonprofit organization that seeks to create a world that understands there is more than one way to have breast cancer. To fulfill its mission of providing trusted information and a community of support to those impacted by the disease, Living Beyond Breast Cancer offers on-demand emotional, practical, and evidence-based content. For over 30 years, the organization has remained committed to creating a culture of acceptance — where sharing the diversity of the lived experience of breast cancer fosters self-advocacy and hope. For more information, learn more about our programs and services.